Assertio Holdings, Inc. (NASDAQ:ASRT ) Q4 2024 Earnings Conference Call March 12, 2025 4:30 PM ET Company Participants Matthew Kreps - IR Brendan O'Grady - CEO Ajay Patel - CFO Conference Call Participants James Sidoti - Sidoti & Company Thomas Flaten - Lake Street Capital Markets, LLC Naz Rahman - Maxim Group Scott Henry - AGP Operator Thank you for standing by. My name is Eric, and I'll be your conference operator today.
LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
CHICAGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed in Lake County Circuit Court, Nineteenth Judicial Circuit, State of Illinois, on behalf of all persons and entities who acquired Assertio Holdings, Inc. (NASDAQ: ASRT) (“Assertio” or the “Company”) common stock issued in exchange for Spectrum Pharmaceuticals, Inc. (“Spectrum”) common stock in connection with Assertio's July 31, 2023 merger with Spectrum (the “Merger”), charging the Company and certain of its current and former senior executives and directors with violations of the federal securities laws (collectively, “Defendants”).
LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective December 23, 2024, the Compensation Committee of the Company's Board of Directors granted Mary Pietryga, the Company's newly-hired Senior Vice President, Chief Commercial Officer, 62,500 restricted stock units (“RSUs”) and 275,000 stock options (“options”).
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee.
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon ® (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for patients with early stage breast cancer (ESBC).
CTV, GRAB, ASRT, POWL and LUV have been added to the Zacks Rank #1 (Strong Buy) List on December 10, 2024.
MKTAY, ASRT, CHH, DRS and BRKL have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2024.
Call Start: 16:30 January 1, 0000 5:03 PM ET Assertio Holdings, Inc. (NASDAQ:ASRT ) Q3 2024 Earnings Conference Call November 11, 2024 04:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - CEO Ajay Patel - SVP & CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Naz Rahman - Maxim Group Scott Henry - Alliance Global Partners Raghuram Selvaraju - H.C. Wainwright Operator Thank you for standing by.
Assertio (ASRT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.01 per share a year ago.